Pfizer (PFE) Stock Forecast & Price Target

$26.36 +0.59 (+2.29%)

(As of 12/20/2024 05:45 PM ET)

Pfizer - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 17 Analyst Ratings

Sell
1

Hold
9

Buy
7

Based on 17 Wall Street analysts who have issued ratings for Pfizer in the last 12 months, the stock has a consensus rating of "Hold." Out of the 17 analysts, 1 has given a sell rating, 9 have given a hold rating, 5 have given a buy rating, and 2 have given a strong buy rating for PFE.

Consensus Price Target

$32.14
21.94% Upside

According to the 17 analysts' twelve-month price targets for Pfizer, the average price target is $32.14. The highest price target for PFE is $45.00, while the lowest price target for PFE is $25.00. The average price target represents a forecasted upside of 21.94% from the current price of $26.36.

Get the Latest News and Ratings for PFE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Pfizer and its competitors.

PFE Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)
Hold	9 Hold rating(s)	8 Hold rating(s)	8 Hold rating(s)	11 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$32.14	$32.92	$34.54	$40.35
Forecasted Upside	21.94% Upside	28.46% Upside	17.84% Upside	42.09% Upside
Consensus Rating	Hold	Moderate Buy	Moderate Buy	Hold

If you see ONE chart today… make it this one (Ad)

$1 Trillion… That’s how much Big Tech is set to spend on AI investment in the coming months—according to Goldman Sachs. This investment is driving an A.I. boom that’s being felt across many industries… Including a specific group of energy tickers since A.I. data centers use a massive amount of power. One of those tickers is CEG, up nearly 600% in the last 3 years… Combined with the upcoming presidential election, we have the recipe for a major shakeup in the market. You see, each time the U.S. elects a new president, one overlooked part of the energy sector tends to see a big move. Fact is… this energy niche is BOOMING.

And expects this underappreciated niche to continue rallying well into 2026.

PFE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PFE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Pfizer Stock vs. The Competition

Type	Pfizer	Medical Companies	S&P 500
Consensus Rating Score	2.47	2.81	2.51
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	21.94% Upside	25,827.32% Upside	14.53% Upside
News Sentiment Rating	Neutral News See Recent PFE News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/18/2024	Truist Financial 2 of 5 stars		Lower Target	Buy ➝ Buy	$36.00 ➝ $32.00	+21.72%
12/11/2024	Guggenheim 2 of 5 stars		Lower Target	Buy ➝ Buy	$35.00 ➝ $33.00	+29.97%
12/10/2024	Bank of America 3 of 5 stars		Reiterated Rating	Neutral	$29.00	+11.03%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hammond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform	$25.00	-3.92%
10/30/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	U. Raffat Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
10/25/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$30.00	+4.71%
Get the Latest News and Ratings for PFE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.
10/23/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$45.00 ➝ $45.00	+55.93%
10/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Breen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$32.00	+7.89%
8/7/2024	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Nakagiri Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy ➝ Strong-Buy
8/7/2024	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform	$28.00 ➝ $34.00	+14.21%
7/31/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$30.00 ➝ $32.00	+4.51%
7/31/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$28.00 ➝ $30.00	-3.23%
7/31/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$30.00 ➝ $31.00	+0.23%
5/2/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$28.00 ➝ $29.00	+4.28%
5/2/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$33.00 ➝ $36.00	+30.62%
3/22/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
1/4/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$32.00	+7.67%
10/16/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$36.00 ➝ $34.00	+0.71%
10/16/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$38.00 ➝ $39.00	+21.46%
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$50.00	+38.66%
6/29/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$47.00 ➝ $40.00	+10.22%
2/7/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Kerry Holford Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$40.00	-8.24%
2/1/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Market Perform	$49.00 ➝ $48.00	+8.70%
2/1/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral	$50.00 ➝ $46.00	+4.17%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 10:19 PM ET.

Should I Buy Pfizer Stock? PFE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, December 12, 2024. Please send any questions or comments about these Pfizer pros and cons to contact@marketbeat.com.

Pfizer
Bull Case

Here are some ways that investors could benefit from investing in Pfizer Inc.:

Pfizer Inc. has a strong market capitalization of approximately $142.98 billion, indicating a robust financial position that can support growth and stability.
The stock is currently trading at $25.23, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
Recent analyst ratings show a consensus average rating of "Moderate Buy," suggesting that many analysts believe the stock has potential for appreciation.
Pfizer Inc. has a diverse portfolio of biopharmaceutical products, which can help mitigate risks associated with reliance on a single product line.
Institutional ownership stands at 68.36%, indicating strong confidence from large investors, which can be a positive signal for retail investors.

Pfizer
Bear Case

Investors should be bearish about investing in Pfizer Inc. for these reasons:

Wolfe Research has issued an "underperform" rating with a price target of $25.00, suggesting that the stock may not perform well in the near term.
Recent price targets from analysts vary significantly, with some as low as $25.00, indicating uncertainty about the stock's future performance.
The price-to-earnings (P/E) ratio of 34.31 is relatively high, which may suggest that the stock is overvalued compared to its earnings potential.
There is a notable presence of sell and hold ratings from analysts, with one sell rating and nine hold ratings, reflecting a cautious outlook on the stock.
Pfizer Inc. faces competitive pressures in the biopharmaceutical market, which could impact its market share and profitability in the future.

PFE Forecast - Frequently Asked Questions

: According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for Pfizer is $32.14, with a high forecast of $45.00 and a low forecast of $25.00.
: 17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There is currently 1 sell rating, 9 hold ratings, 5 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PFE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PFE, but not buy additional shares or sell existing shares.
: According to analysts, Pfizer's stock has a predicted upside of 21.94% based on their 12-month stock forecasts.
: Over the previous 90 days, Pfizer's stock had 1 upgrade by analysts.
: Pfizer has been rated by research analysts at Bank of America, Cantor Fitzgerald, Citigroup, Evercore ISI, Guggenheim, Sanford C. Bernstein, Truist Financial, and Wolfe Research in the past 90 days.
: Analysts like Pfizer less than other "medical" companies. The consensus rating for Pfizer is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how PFE compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

This page (NYSE:PFE) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pfizer (PFE) Stock Forecast & Price Target